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Abstract: 
Objectives: To inform the design of randomized clinical trials in early stage manifest Huntington’s 
Disease through analysis of longitudinal data from TRACK-Huntington’s Disease (TRACK-HD), a 
multi-centre observational study. 
Methods: We compute sample sizes required for trials with candidate clinical, functional and 
imaging outcomes, whose aims are to reduce rates of change. The calculations use a two-stage 
approach: first using linear mixed models to estimate mean rates of change and components of 
variability from TRACK-HD data, and second using these to predict sample sizes for a range of 
trial designs.  
Results: For each outcome the primary drivers of required sample size were the anticipated 
treatment effect and the duration of treatment. Extending durations from one to two years 
yielded large sample size reductions. Including interim visits, and incorporating stratified 
randomization on predictors of outcome together with covariate adjustment, gave more modest, 
but non-trivial, benefits. Caudate atrophy expressed as a percentage of its baseline, gave smallest 
sample sizes.  
Discussion: Here we consider potential required sample sizes for clinical trials estimated from 
naturalistic observation of longitudinal change.  Choice amongst outcome measures for a trial 
must additionally consider their relevance to patients, and the expected effect of the treatment 
under study. For all outcomes considered our results provide compelling arguments for two-year 
trials, and we also demonstrate benefits of incorporating stratified randomization coupled with 
covariate adjustment, particularly for trials with caudate atrophy as the primary outcome. The 
benefits of enrichment are more debatable, with statistical benefits offset by potential 
recruitment difficulties and reduced generalizability.  
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Background: 
Other than interventions targeting chorea, clinical trials testing therapeutics in Huntington’s 
disease (HD) have not provided evidence of efficacy1. There are several potential reasons for 
these failures, including a real absence of effect, and poor choice of design and outcomes. New 
classes of drugs such as huntingtin (HTT) lowering therapies are now entering clinical trials2. Thus, 
there is need for assessment of trial designs to ensure that future trials are optimally designed. 
Choosing the most appropriate trial design and outcome measure involves consideration of many 
factors, including relevance of outcomes to patients, and treatment target.  Statistical efficiency,  
measured by the sample size necessary to detect clinically meaningful treatment effects is also 
key, and is our focus here.  
Currently we lack data from HD clinical trials illustrating how potential outcomes behave in 
response to an effective intervention. In such situations trial design may be informed by other 
data, such as that from longitudinal cohort studies, with decisions informed by modelling and 
simulation3, 4. Here we exploit the TRACK-HD longitudinal study5-8. We consider interventions 
aiming to alter rates of disease progression. Accordingly, outcome measures are subject-specific 
rates of change, rather than absolute levels, of structure and function. We model the longitudinal 
TRACK-HD data using linear mixed models9 that explicitly estimate between- and within-subject 
components of variance, thereby allowing prediction of statistical efficiency for different trial 
designs. Specifically, we consider: a) choice of outcome; b) duration of follow-up and assessment 
periodicity; c) stratified randomization using baseline measures potentially predictive of 
outcome, coupled with statistical adjustment for these measures; (d) enrichment using such 
baseline measures; e) plausible dropout patterns.  
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Methods: 
In TRACK-HD5-8 HD patients with early stage disease, pre-manifest gene carriers and controls 
were assessed at baseline, 12, 24, and 36 months at sites in London, Paris, Leiden and Vancouver. 
Here we only consider the early-stage HD patients and controls.  Using the baseline Unified 
Huntington’s Disease Rating Scale (UHDRS) Total Functional Capacity (UHDRS-TFC) score10, early-
HD patients were designated either stage 1 (UHDRS-TFC 11-13) or stage 2 (UHDRS-TFC 7-10). 
We selected six potential outcomes based on their high frequency of use in HD clinical research11: 
the UHDRS-TFC, the UHDRS Total Motor Score (UHDRS-TMS)12, the Symbol Digit Modalities Test 
(SDMT) score, the speeded tapping inter-onset interval standard deviation (IOI-SD) of the 
quantitative motor assessments for the non-dominant hand13, whole brain atrophy and caudate 
atrophy. Changes in whole brain and caudate volumes were measured using the boundary shift 
integral (BSI) methodology14 and the resultant rates of change numerically expressed in three 
ways: i) ml per year, which represents raw volume loss15 (mL), ii) annualized percentage of the 
volume of the baseline region of interest (%base)6 and iii) annualized percentage of total 
intracranial volume (%ICV), a surrogate for maximal premorbid total brain volume.  
We assess trial designs using extensions of previous methodology16, 17. This involves building 
linear mixed models describing the pattern of the repeated measures, and then using these 
models to predict sample size requirements for different designs. We restrict attention to two-
arm parallel trials in which treatment is expected to reduce the rate of progression by a constant 
amount throughout follow-up. We start with simple trials with one pre-randomization visit and 
one at the end of follow-up and then i) investigate the effects of incorporating interim visits at 
which efficacy measures are also made, ii) make allowance for plausible missing data patterns 
and iii) consider the potential utilization of information on covariates such as CAG repeat length. 
In clinical trials covariates can be utilized for various reasons18, and in various ways. We here 
consider two: i) stratified randomization coupled with covariate adjustment, where 
randomization is adapted to balance factors thought to influence outcomes; and, ii) sample 
enrichment, which aims to increase statistical power by restricting trial entry to those for whom 
treatment effects are expected to be largest. We also allow for the fact that the same factor may 
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be used for both enrichment (limiting trial entry to values within a specified range), and for 
further stratification within the selected range.  
Sample size calculations require specification of the anticipated treatment effect. This choice will 
not affect the relative merits of the designs considered (if one design requires 10% more patients 
than another for one effect it will also require 10% more patients for others), so when making 
comparisons the choice is to some extent arbitrary. Nonetheless, it is informative to present 
results for particular anticipated effects, so we give results for 20% and 40% reductions in the 
mean rate of change, choices that are typical of the effects sought in larger HD trials19-21 (see 
discussion). For UHDRS-TMS and UHDRS-TFC we consider treatment effects that are simple 
percentage reductions in the mean rate of change.  All of the other potential outcomes 
considered here change over time even in people without disease8. Brain volumes decrease due 
to normal ageing, whilst performance on motor and cognitive tasks improve due to practice 
effects. A 100% effective treatment would most plausibly result in the mean change being the 
same as that in healthy controls. Therefore for outcomes other than UHDRS-TMS and UHDRS-
TFC, we (like others17, 22, 23) consider treatment effects that are 20 and 40% reductions in the 
excess mean rate of change (over and above that seen in healthy controls). We also make the 
commonly adopted assumption that variability will be unaltered by treatment such that 
variability in both arms will mimic that seen in the early-HD patients.  
Statistical methods  
The two-stage statistical approach builds on previously described principles16. It is described in 
detail in the statistical appendix, and summarized here. The first stage develops appropriate 
linear mixed models for each outcome. The second uses parameter estimates from these models 
to predict the expected mean and variance of observed treatment effects, and hence required 
sample sizes, for each design of interest.  
For the non-imaging outcomes (UHDRS-TMS, UHDRS-TFC, SDMT and speeded tapping IOI-SD) the 
basic model is a standard random slopes model relating the outcome to time since 
randomization, with the addition of random site and site-by-visit interactions. UHDRS-TMS, 
UHDRS-TFC and the speeded tapping IOI-SD were all transformed, as described in the appendix, 
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so that residuals better approximated a normal distribution. Models were fitted in the early-HD 
patients and, for SDMT and speeded tapping, jointly with an analogous model in controls. To 
compute sample sizes for designs incorporating stratified randomization coupled with covariate 
adjustment, fixed main effects of age, CAG repeat length, disease burden (a combination of CAG 
repeat length and age24) and disease stage and their interactions with time were added. 
Participants were included in the analysis if at least two (i.e. at least one measure of change) of 
the four measurements were available.  
For the imaging outcomes the basic models are extensions of the models recommended for the 
analysis of repeated “direct” measures of change25, with further extensions analogous to those 
for the non-imaging variables, except that main effects of baseline volume instead of disease 
stage were used. Participants were included if they had at least one measurement of change.    
To perform sample size calculations for enriched designs, we additionally fitted all models in 
subsets formed by separately dichotomizing on CAG repeat length (>/≤ 43, the median), disease 
burden24 (>/≤ 382.2 (the median value)), disease stage (I/II) and baseline brain and caudate 
volumes as a percentage of ICV (each dichotomized at the median from the full early-HD cohort). 
In these calculations we continue to assume stratified randomization and statistical adjustment 
for the enrichment factor and other relevant covariates.  
As in earlier applications26 uncertainty in sample size calculations was estimated using the 
bootstrap27. A pattern-mixture was used to evaluate the impact of dropouts and missing data28, 
29, with assumptions concerning these based on the patterns seen in TRACK-HD. 
We present required sample sizes for 90% power to detect 20 and 40% treatment effects (only 
20% in the appendices).  Our results can  be converted to required sample sizes for any other 
treatment effect since sample sizes are inversely proportional to the square of the treatment 
effect: e.g. switching from a 20% to a 25% reduction multiplies all sample sizes by 0.64 ((20/25)2). 
Analogously, switching from 90% to 80% power multiplies all sample sizes by 0.747 (see 
appendix).  
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Results: 
We analysed data from 123 early-HD patients and 123 controls (Table 1).  For the non-imaging 
variables around three-quarters of the participants provided information at all visits, with less 
than 10% providing no data (through having measures at only one visit and hence no information 
on change over time). For the imaging variables just over 50% have measures of change from 
baseline to all of the follow-up visits, with around 10% of controls and 15% of early-HD patients 
providing no change measures (Supplementary Table 1). 
Required sample sizes differ markedly between the imaging and non-imaging outcomes (Table 
2). For the clinical outcomes (UHDRS-TMS and TFC) a one year trial with 90% statistical power to 
detect a 20% treatment effect requires of the order of 6000 (3000 per arm) patients (for a design 
that only stratifies by, and adjusts for, site in the stratified randomization and statistical analysis). 
For the imaging outcomes the analogous numbers are of the order of 1000, whilst for SDMT 
around 3000 patients are required. The sample size is also highly dependent on the assumed 
treatment effect: doubling the effect reducing the required sample size by a factor of four.   
Other than the assumed treatment effect, for each outcome the primary driver of required 
sample size is follow-up duration. Increasing follow-up from one to two years has a greater effect 
than the further increase to three years (Table 2). This is because for all measures the standard 
deviation of the annualized rate of change declines to an asymptote (representing the between-
subject standard deviation) as follow-up increases, with the steepness of the decline 
progressively decreasing (Figure 1).  
The impact of adding interim visits at which efficacy measurements are made is much less 
marked. Adding one visit mid-way through follow-up has little impact on required sample sizes 
for the one- and two-year designs, but six-monthly interim visits do somewhat reduce 
requirements for the two and three-year designs. For a two-year clinical trial with six-monthly 
interim visits the most statistically efficient outcome was caudate atrophy expressed as a 
percentage of baseline volume, with 298 participants (149 per arm (95% CI (117, 269)) required 
for 90% statistical power to detect a 20% reduction. The analogous numbers for SDMT (the best 
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non-imaging outcome) were 412 (272, 700), with those for the other non-imaging outcomes 
being roughly double this (Table 2).  
Adopting a design with a stratified randomization that incorporates factors other than site, and 
carrying out a statistical analysis that adjusts for these factors, can reduce sample size 
requirements (see Table 3 for two-year designs with six-monthly interim visits, supplementary 
table 2 for other designs). Reductions are fairly modest for the non-imaging outcomes; for a  two-
year clinical trial with six-monthly interim visits stratifying by (and adjusting for) age, CAG repeat 
length, disease burden and disease stage in addition to site only reduces samples sizes by 
between 5 and 15% (Table 3, scenarios A. and B.).  However, for caudate atrophy gains are larger. 
For this outcome required sample sizes for a two-year trial with six-monthly interim visits are 
estimated to be smallest when atrophy is expressed as a percentage of baseline; here stratifying 
by and adjusting for age, CAG repeat length, disease burden and baseline caudate volume 
reduces the required sample size by a substantial 42% (Table 3, scenarios A. and B.). 
Using inclusion/exclusion criteria for enrichment can also reduce sample size requirements (see 
Table 3, scenarios D. to F. for two-year designs with six-monthly interim visits, supplementary 
tables 3-5 for other designs). For example, for caudate atrophy (analyzed as a percentage of 
baseline) estimated sample sizes are approximately halved by restricting to patients with CAG 
repeat lengths of 44 and above. For SDMT, restriction to either those with greatest disease 
burden, or to stage II patients, reduces sample size requirements by around a third. However, it 
should be noted that in our exploration of enrichment, confidence intervals are wider than in 
earlier analyses because of the reduced numbers of patients considered. This imprecision is 
illustrated by the fact that for the UHDRS measures restriction to stage II patients actually 
increases estimated requirements. 
Sample size calculations should always take into account dropouts and other anticipated missing 
data. More missing data is expected for imaging variables (through inadequate scans and because 
some are unable to tolerate imaging). The allowance that we make for missing data (table 3 
scenario C. for two-year designs with six-monthly interim visits, supplementary table 6 for other 
designs) which base assumptions about missing data from TRACK-HD follow-up reflect this. 
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Including interim visits at which efficacy measures are made also has greater benefit when 
dropouts are anticipated. For example, for caudate atrophy (expressed as a percentage of 
baseline) adding six-monthly interim visits to a two-year trial reduces estimated sample size 
requirements by 19% (supplementary table 6) for a stratified design with dropouts compared 
with only 13% (supplementary table 2) when no dropouts are anticipated (and 9% (table 2) in a 
design only stratified by site).     
Based on our analyses our general recommendation (figure 2, table 3 scenario C.) is for two-year 
clinical trials with six-monthly interim visits. With appropriate allowance for missing data, 
stratification and statistical adjustment (as described above), but no enrichment, a trial with 90% 
statistical power to detect a 20% treatment effect requires 107 (95% CI (90, 154)) patients per 
arm if caudate atrophy (expressed as a percentage of baseline) is the chosen outcome variable. 
With this design and SDMT as the outcome, sample sizes are multiplied by an approximate factor 
of four (410 (277, 712) per arm).   
 
Discussion: 
Sample size and its corresponding resource requirements are important criteria when designing 
clinical trials. We here extend earlier methodology to compute required sample sizes for 
various HD clinical trial designs. Several interventions intended to slow the progression of HD 
have been tested in long-term clinical trials19-21, 30-32. None found statistically significant 
treatment effects. There are likely multiple reasons for these failures, including the absence of 
valid targets, pharmacokinetic limitations such as lack of penetration of the blood brain barrier, 
and insufficient statistical power.   
Since no intervention in HD has been shown to be efficacious in slowing deterioration, defining 
clinically meaningful effects is problematic. Relative comparisons between required sample 
sizes for different designs are not contingent on the choice of treatment effect, but nonetheless 
it is useful to give context to comparisons by focusing on particular effects. Accordingly, we 
present results for 20% and 40% reductions in the mean rate of decline, reductions that are 
typical of those that the larger HD trials have attempted to detect. For example, the sample size 
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justification in the CARE trial20 was based on an anticipated 40% reduction in the rate of TFC 
decline, whilst that for the Riluzole trial19 was based on a mean 1 point change in TFC, which 
corresponds to an approximate 40% reduction (the mean change in the trial was around 2.4), 
whilst that for the coenzyme Q10 trial21 was also based on a mean 1 point change in TFC, 
approximately 20% of the mean change of 4.5 seen during follow-up. Other HD trials31, 32 have 
based their calculations on much larger, arguably over-optimistic, effects. Effects of between 
20% and 40% have also been sought in other neurological diseases. For example, the successful 
MS-STAT trial33 in multiple sclerosis was powered to detect a 25% reduction in whole brain 
atrophy. A review of trials in Alzheimer’s disease23 also considered 25% reductions (and 50% 
reductions in excess rate over and above that seen in people with disease). Reductions of 
between 20% and 40% represent, in our view, a clinically meaningful slowing of decline that can 
potentially be demonstrated in a trial of reasonable size and duration.                
The size of the anticipated treatment effect has a strong, well-known impact on sample size; 
treatments anticipated to be twice as effective require only 25% of the participants. The relative 
merits of the various designs that we consider are unaffected by our choice of anticipated 
treatment effect, or by our choice of statistical power: varying these simply multiplies the 
required sample sizes for each design by the same factor. However, although relative impact is 
not affected by such considerations, the feasibility of a given design does depend on whether the 
sample size is achievable.  
Our findings show that for trials where the outcome is a rate of change, the primary driver of 
sample size (other than the anticipated treatment effect) is length of follow-up.  Larger gains in 
efficiency come from extending follow-up from one to two years compared with a further 
extension to three years. Increasing the number of interim visits has less impact: however, their 
value increases when allowance is made for anticipated dropouts and missing values. Due to 
space limitations, we have considered only regularly spaced interim visits here. As in other 
applications17 our methodology can potentially be used to investigate the benefits of more 
frequent, or irregularly spaced, interim visits, but interpretation must be cautious when source 
data was not collected at such frequencies. When visits are frequent within-subject correlation 
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may differ in ways that are difficult to predict confidently. Inclusion of interim visits does increase 
costs and burden on subjects, especially in studies involving imaging. However, since some 
investigational products may require more frequent visits to evaluate safety, additional efficacy 
outcome measurements could be collected concomitantly, so reducing costs. Also, including 
interim assessments can support design decisions about future trials.  
Stratification by factors such as age, CAG, disease burden, disease stage and baseline volume 
measures can reduce sample sizes, if coupled with appropriate statistical analysis. Our results 
potentially slightly over-estimate the benefits of such strategies since we assume that perfect 
balance on multiple stratification factors can be achieved, which may in practice not be possible, 
particularly when sample sizes are small and/or large numbers of sites are involved. Some 
stratification factors may then have to be omitted or minimization34 considered as an alternative 
to stratified randomization. Enrichment is more contentious. It is possible that use of some 
treatments may ultimately be restricted to patients with higher CAG lengths and/or that 
enrichment may be necessary for targeted therapies that are only anticipated to work in a 
restricted population. In our analysis enrichment by restriction to patients with CAG repeat 
lengths of 44 and above reduced estimated sample sizes by up to 50%. However, it also reduced 
the available population by around half. Further, our calculations assume that the percentage 
reduction in rates of change achievable through treatment is unaltered by enrichment, implying 
that absolute reductions increase, which may be unrealistic.  
Our most statistically efficient outcome was caudate atrophy expressed as a percentage of 
baseline volume. Without stratification or enrichment, 330 participants (165 per arm (95% CI 
(130, 280))) are required for 90% statistical power to detect a 20% reduction in caudate atrophy 
rates in a two-year follow-up trial with no interim visits. This required sample size can be reduced 
to an estimated 87 per arm (95% CI (73, 125)) in a design that scans participants every six months 
and stratifies by age, CAG repeat length and baseline caudate volume: although a plausible 
assumption concerning missing values gives a required sample size of 107 (95% CI (90, 154)) per 
arm.  Of the non-imaging outcomes considered, the SDMT was most efficient (at least when 
practice effects were allowed for). 
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Choice of the most appropriate primary outcome measure for a particular intervention cannot 
be based only on sample size; biological plausibility, the expected effects of the intervention, the 
stage of the disease and the regulatory path forward all need consideration. We cannot assume 
that an intervention targeting the physiopathology of the disease will equally and simultaneously 
affect all outcomes. For example, a therapy aimed at maintaining white matter may not have a 
measurable effect on striatum structure Likewise, SDMT but not UHDRS-TMS, is likely to capture 
an intervention targeting cognition. It is also possible that different effects will occur in different 
timeframes, these sometimes being unexpected. For example, clinical trials that tested anti-
amyloid interventions in Alzheimer’s disease showed an increase in brain atrophy, when a 
decrease was expected; despite some cognitive improvement and pharmacodynamic proof of 
amyloid reduction by PET scan35, 36. Accordingly trials should include a range of secondary 
outcomes and have built-in learning opportunities for the validation of others. Ideally, clinical 
trials should favor outcomes that best represent the disease from patients’ perspectives. 
Unfortunately those that perhaps best fit this criterion are UHDRS-TMS and UHDRS-TFC, which 
we found to be the least statistically efficient. Further, both these scales may be even less 
efficient in a trial, since the increases in scores seen in TRACK-HD might in part be an artifact, 
arising from observers’ expectation of deterioration without treatment. In trials they may also 
be affected by placebo effects arising from expectations of benefit. Structural Imaging outcomes 
are the most efficient, but they raise complex problems of translation to clinical relevance: so 
may be most appropriate in “proof of concept” phase II trials.  
One limitation of our analysis is that we used a single naturalistic study conducted in just four 
highly specialized sites. Although absolute levels of the outcome variables differed between sites, 
rates of change did not differ markedly. The statistical models that we used did allow for 
variability in changes over time between sites through the inclusion of site-by-visit interaction 
terms, but they did not allow the anticipated treatment effect on rate of change to differ across 
sites. This means that our results can only be cautiously generalized to multi-centre studies with 
less specialized sites, where greater heterogeneity might be anticipated. Additionally, there is 
some evidence37 that dropout rates in clinical trials may be higher than observed in TRACK-HD. 
Also, we do not have information on possible placebo effects which could be important, 
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particularly for non-imaging outcomes38. Despite these limitations, we believe our work provides 
a useful contribution to the design of trials in early-HD. It provides a clear indication of the best 
duration, shows the benefits of stratified randomization when coupled with appropriate 
statistical analysis, and gives a firm basis for the choice of analytical method for imaging 
outcomes.  
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